Last reviewed · How we verify
NCT03758963
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
NA trial testing R:GEN Selective Retina Therapy in Central Serous Chorioretinopathy in 63 participants. Completed in 20 June 2018.
2 April 2018
Quick facts
| Lead sponsor | CynosureLutronic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 63 |
| Start date | 30 March 2016 |
| Primary completion | 2 April 2018 |
| Estimated completion | 20 June 2018 |
| Sites | 6 locations across South Korea |
Drugs / interventions tested
- R:GEN Selective Retina Therapy
Conditions studied
- Central Serous Chorioretinopathy — all drugs for Central Serous Chorioretinopathy →
Sponsor
CynosureLutronic — full company profile →
Who can join
Adults 19 to 55, any sex, with Central Serous Chorioretinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical study is to evaluate the efficacy and safety of selective retina therapy (SRT) using R:GEN, an approved laser device, in patients with central serous chorioretinopathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.
Oh J, Yoon CK, Kim BH, Yu HG. · · 2021 · cited 12× · PMID 33307626 · DOI 10.3341/kjo.2020.0112
Verify or expand the search:
- PubMed search for NCT03758963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Central Serous Chorioretinopathy
Currently open trials in the same condition.
- NCT06527326 — the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy · NA · recruiting
- NCT06346405 — Central Serous Chorioretinopathy and Micropulse Laser Treatment · recruiting
- NCT05570591 — Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy · NA · recruiting
- NCT05589974 — Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy · recruiting
Other CynosureLutronic trials
Trials by the same sponsor.
- NCT06117293 — Safety and Efficacy Evaluation of the Mosaic Ultra Device · NA · unknown
- NCT06152900 — Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning · NA · completed
- NCT04207047 — Histologic Evaluation of Tissue Following Lutronic System Exposure · NA · unknown
- NCT04208100 — Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands · NA · active not recruiting
- NCT03534609 — Lutronic Genius System for Neck Treatment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03758963 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CynosureLutronic
- Last refreshed: 29 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03758963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing